On June 30, Hansoh Pharmaceutical fell 3.03% in regular trading, trading at HKD 29.4/share, with turnover of approximately HKD 93.81 million. The decline came amid broad-based weakness across the pharmaceutical sector.

Among sector peers, CSPC Pharma fell 1.82%, Luye Pharma fell 6.38%, Hengrui Pharma fell 2.15%, SBP Group fell 2.0%, and Asymchem fell 5.42%. The pullback follows a strong session on June 29, when Hansoh Pharmaceutical surged 4.88% driven by concentrated pipeline catalysts and sector-wide strength. The company has recently seen multiple positive developments including NDA acceptance for its ADC drug with potential deal value exceeding USD 1.5 billion, shareholder approval of a share buyback authorization of up to 10%, and NDA filings for HS-10568 injection and weight-loss drug olatorepatide injection, accelerating its innovation pipeline commercialization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)